GlassScriptPhysician profile
Paul Slota
NPI 1104877257
$5,133.65
in general payments reported to CMS, 2019-2025
42 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $299 · 2021: $739 · 2022: $1,006 · 2023: $875 · 2024: $1,047 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.38 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $643.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $489.78 | 2020-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $482.99 | 2021-2024 | Verquvo, Janumet |
| Amgen INC. | $409.47 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $250.24 | 2019-2024 | |
| Abiomed | $216.60 | 2021-2024 | Impella |
| Pfizer INC. | $214.94 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.63 | 2021-2025 | |
| Acist Medical Systems, INC. | $186.83 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $184.42 | 2024 | Arcalyst |
| Boston Scientific Corporation | $131.57 | 2020-2025 | Watchman Flx, Rotapro |
| Atricure, INC. | $129.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.82 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $119.33 | 2019-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.38 | 2019-2024 | Jardiance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $113.88 | 2019-2022 | |
| Edwards Lifesciences Corporation | $111.53 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $106.16 | 2023-2025 | Inspire |
| Kestra Medical Technology Services, INC. | $104.14 | 2022-2024 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $88.43 | 2019-2020 | |
| Daiichi Sankyo INC. | $80.62 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $75.00 | 2021 | |
| Bard Peripheral Vascular, INC. | $67.65 | 2023-2024 | Venclose Maven Catheter |
| Astrazeneca Pharmaceuticals LP | $67.20 | 2019-2025 | Wainua |
| Cardiovascular Systems INC. | $50.44 | 2019-2021 | |
| Elutia, INC. | $45.55 | 2020-2022 | |
| Cvrx, INC. | $37.92 | 2023-2025 | Barostim Neo System |
| Nevro Corp. | $36.10 | 2024 | Senza |
| Abbott Laboratories | $34.35 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $25.06 | 2023 | Arcalyst |
| Tactile Systems Technology INC | $24.30 | 2022 | |
| Corvista Health, INC. | $23.11 | 2025 | Corvista System |
| Cardiva Medical, INC. | $21.58 | 2020 | |
| Medtronic, INC. | $19.30 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.16 | 2021 | |
| Novo Nordisk INC | $16.92 | 2023 | Ozempic, Rybelsus |
| Ekos Corporation | $16.29 | 2019 | |
| Glaxosmithkline, LLC. | $15.91 | 2025 | Shingrix |
| Irhythm Technologies, INC. | $13.19 | 2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $12.56 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 | |
| Infobionic, INC | $2.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Slota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.